COVID-19 Vaccine Intention among Healthcare Workers in Saudi Arabia: A Cross-Sectional Survey
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Sample
2.3. Measures
2.3.1. Trust in Vaccines, Vaccine Manufacturers, and Health Authorities
2.3.2. Intention to Vaccinate
2.4. Exploratory Variables
2.5. Statistical Analysis
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Alagoz, O.; Sethi, A.K.; Patterson, B.W.; Churpek, M.; Safdar, N. Effect of timing of and adherence to social distancing measures on COVID-19 burden in the United States. Ann. Intern. Med. 2021, 174, 50–57. [Google Scholar] [CrossRef]
- Andre, F.E.; Booy, R.; Bock, H.L. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull. World Health Organ. 2008, 86, 140–146. [Google Scholar] [CrossRef] [PubMed]
- Palache, A.; Oriol-Mathieu, V.; Abelin, A.; Music, T. Seasonal influenza vaccine dose distribution in 157 countries (2004–2011). Vaccine 2014, 32, 6369–6376. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zimmer, C.; Corum, J.; Wee, S.-L. 2021 Coronavirus Vaccine Tracker. The New York Times. 2020. Available online: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html (accessed on 25 April 2021).
- Sallam, M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines 2021, 9, 160. [Google Scholar] [CrossRef] [PubMed]
- Friedrich, M.J. WHO’s top health threats for 2019. J. Am. Med. Assoc. 2019, 321, 1041. [Google Scholar] [CrossRef]
- Kwok, K.O.; Li, K.-K.; Wei, W.I. Influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: A survey. Int. J. Nurs. Stud. 2021, 114, 103854. [Google Scholar] [CrossRef] [PubMed]
- Noh, E.B.; Nam, H.K.; Lee, H. Which Group Should be Vaccinated First?: A Systematic Review. Infect. Chemother. 2021, 53, 261–270. [Google Scholar] [CrossRef]
- Alshamrani, M.M.; El-Saed, A.; Al Zunitan, M.; Almulhem, R.; Almohrij, S. Risk of COVID-19 morbidity and mortality among healthcare workers working in a Large Tertiary Care Hospital. Int. J. Infect. Dis. 2021, S1201-9712(21)00564-6. [Google Scholar] [CrossRef]
- European Centre for Disease Prevention and Control. Vaccine Hesitancy among Healthcare Workers and Their Patients in Europe—A Qualitative Study; ECDC: Stockholm, Sweden, 2015. [Google Scholar]
- Sage Working Group. Report of the Sage Working Group on Vaccine Hesitancy’ Was Used as a Guide in Preparing the Questionnaire. 2014. Available online: https://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf (accessed on 10 January 2021).
- Ferrari, M. Almost 1.5 mln Worshippers Visit Grand Mosque in First Ten Days of Ramadan. Al Arabiya News, April 2021. Available online: https://english.alarabiya.net/coronavirus/2021/04/25/Almost-1-5-mln-worshippers-visit-Grand-Mosque-in-first-ten-days-of-Ramadan (accessed on 25 April 2021).
- Bashir, S.; Alabdulkarim, N.; Altwaijri, N.; Alhaidri, N.; Hashim, R.; Nasim, E.; Mir, A.; Albaradie, R.; Habib, S.S.; Abualait, T. The battle against the COVID-19 pandemic- a perspective from Saudi Arabia. One Health 2021, 12, 100229. [Google Scholar] [CrossRef] [PubMed]
- Arab News. Saudi Health Minister: COVID-19 Vaccine a ‘Must’ for Hajj Healthcare Workers. Arab News, 2 March 2021. Available online: https://www.arabnews.com/node/1818441/saudi-arabia (accessed on 27 April 2021).
- Al-Mohaithef, M.; Padhi, B.K. Determinants of COVID-19 Vaccine Acceptance in Saudi Arabia: A Web-Based National Survey. J. Multidiscip. Healthc. 2020, 13, 1657–1663. [Google Scholar] [CrossRef]
- AlAwadhi, E.; Zein, D.; Mallallah, F.; Haider, N.B.; Hossain, A. Monitoring COVID-19 Vaccine Acceptance in Kuwait During the Pandemic: Results from a National Serial Study. Risk Manag. Healthc. Policy 2021, 14, 1413–1429. [Google Scholar] [CrossRef] [PubMed]
- Qattan, A.M.N.; Alshareef, N.; Alsharqi, O.; Al Rahahleh, N.; Chirwa, G.C.; Al-Hanawi, M.K. Acceptability of a COVID-19 Vaccine Among Healthcare Workers in the Kingdom of Saudi Arabia. Front. Med. (Lausanne) 2021, 8, 644300. [Google Scholar] [CrossRef]
- Alfageeh, E.I.; Alshareef, N.; Angaw, K.; Alhazmi, F.; Chirwa, G.C. Acceptability of a COVID-19 Vaccine among the Saudi Population. Vaccines 2021, 9, 226. [Google Scholar] [CrossRef]
- Ledda, C.; Costantino, C.; Cuccia, M.; Maltezou, H.C.; Rapisarda, V. Attitudes of Healthcare Personnel towards Vaccinations before and during the COVID-19 Pandemic. Int. J. Environ. Res. Public Health 2021, 18, 2703. [Google Scholar] [CrossRef] [PubMed]
- Kaplan, A.K.; Sahin, M.K.; Parildar, H.; Guvenc, I.A. The willingness to accept the COVID-19 vaccine and affecting factors among healthcare professionals: A cross-sectional study in Turkey. Int. J. Clin. Pract. 2021, e14226. [Google Scholar] [CrossRef]
- Neumann-Böhme, S.; Varghese, N.E.; Sabat, I.; Barros, P.P.; Brouwer, W.; van Exel, J.; Schreyögg, J.; Stargardt, T. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur. J. Health Econ. 2020, 21, 977–982. [Google Scholar] [CrossRef]
- Saudi Gazette Report. MoH: 55% of COVID-19 Infections among Women. Saudi Gazette, 18 April 2021. Available online: https://saudigazette.com.sa/article/605720 (accessed on 24 April 2021).
- Huang, B.; Cai, Y.; Li, N.; Li, K.; Wang, Z.; Li, L.; Wu, L.; Zhu, M.; Li, J.; Wang, Z.; et al. Sex-based clinical and immunological differences in COVID-19. BMC Infect. Dis. 2021, 21, 647. [Google Scholar] [CrossRef]
- Aslaner, H.; Aslaner, H.A.; Gokcek, M.B.; Benli, A.R.; Yildiz, O. The Effect of Chronic Diseases, Age and Gender on Morbidity and Mortality of COVID-19 Infection. Iran J. Public Health 2021, 50, 721–727. [Google Scholar]
- Gagneux-Brunon, A.; Detoc, M.; Bruel, S.; Tardy, B.; Rozaire, O.; Frappe, P.; Botelho-Nevers, E. Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: A cross-sectional survey. J. Hosp. Infect. 2021, 108, 168–173. [Google Scholar] [CrossRef]
- Yu, Y.; Lau, J.T.; She, R.; Chen, X.; Li, L.; Li, L.; Chen, X. Prevalence and associated factors of intention of COVID-19 vaccination among healthcare workers in China: Application of the Health Belief Model. Hum. Vaccin. Immunother. 2021, 1–9. [Google Scholar] [CrossRef]
- Paul, E.; Steptoe, A.; Fancourt, D. Attitudes towards vaccines and intention to vaccinate against COVID-19, Implications for public health communications. Lancet Reg. Health Eur. 2021, 1, 100012. [Google Scholar] [CrossRef] [PubMed]
- Coe, A.B.; Elliott, M.H.; Gatewood, S.B.S.; Goode, J.-V.R.; Moczygemba, L.R. Perceptions and predictors of intention to receive the COVID-19 vaccine. Res. Soc. Adm. Pharm. 2021, S1551-7411, 00164–00169. [Google Scholar] [CrossRef]
- Yan, E.; Lai, D.W.L.; Lee, V.W.P. Predictors of Intention to Vaccinate against COVID-19 in the General Public in Hong Kong: Findings from a Population-Based, Cross-Sectional Survey. Vaccines 2021, 9, 696. [Google Scholar] [CrossRef] [PubMed]
- Alzeer, A.A.; Alfantoukh, L.A.; Theneyan, A.; Eid, F.B.; Almangour, T.A.; Alshememry, A.K.; Alhossan, A.M. The influence of demographics on influenza vaccine awareness and hesitancy among adults visiting educational hospital in Saudi Arabia. Saudi Pharm. J. 2021, 29, 188–193. [Google Scholar] [CrossRef]
- Kumari, A.; Ranjan, P.; Chopra, S.; Kaur, D.; Kaur, T.; Kalanidhi, K.B.; Goel, A.; Singh, A.; Baitha, U.; Prakash, B.; et al. What Indians Think of the COVID-19 vaccine: A qualitative study comprising focus group discussions and thematic analysis. Diabetes Metab. Syndr. Clin. Res. Rev. 2021, 15, 679–682. [Google Scholar] [CrossRef] [PubMed]
- MOH News. MOH Begins Vaccinating 12–18 Age Group with Pfizer Vaccine. Ministry of Health. 27 June 2021. Available online: https://www.moh.gov.sa/en/Ministry/MediaCenter/News/Pages/News-2021-06-27-008.aspx (accessed on 8 July 2021).
Parameter | Category | N (%) |
---|---|---|
Age (years) | 18–29 y | 392 (58.2) |
30–49 y | 251 (37.2) | |
50–64 y | 27 (4) | |
Above 64 y | 4 (0.6) | |
Sex | Male | 350 (51.9) |
Female | 324 (48.1) | |
Nationality | Saudi | 410 (60.8) |
Non-Saudi | 264 (39.2) | |
Current work/study place in Saudi Arabia | Northern Region | 14 (2.1) |
Southern Region | 10 (1.5) | |
Central Region | 555 (82.3) | |
Eastern Region | 60 (8.9) | |
Western Region | 35 (5.2) | |
Type of Practice | Governmental | 154 (22.8) |
Private | 488 (72.4) | |
Both | 32 (4.7) | |
Medical Condition | Healthy | 573 (85) |
Has chronic disease/s | 101 (15) | |
Profession | Medical doctor | 76 (11.3) |
Dentist | 191 (28.3) | |
Nurse | 41 (6.1) | |
Pharmacist | 29 (4.3) | |
Dental assistant/Hygienist Medical | 6 (0.9) | |
/Dental technician | 6 (0.9) | |
Health care student | 238 (35.3) | |
Other health profession | 87 (12.9) |
No | Question | Participants’ Response n (%) |
---|---|---|
1 | Have you had COVID-19? | Yes 102 (15.1) No 572 (84.9) |
2 | Have you taken the COVID-19 vaccine? | Yes 67 (9.9) No 607 (90.1) |
3 | Have you been updating yourself on the development of vaccines against COVID-19? | Yes 563 (83.5) No 111 (16.5) |
4 | In your opinion, how would you rate the severity of COVID-19? | Mild 25 (3.7) Moderate 315 (46.7) Severe 334 (49.6) |
5 | How would you rate your compliance with COVID-19 preventive guidelines? | Good 472 (70) Moderate 188 (27.9) Poor 14 (2.1) |
6 | To what extent are you anxious about contracting (getting infected with) COVID-19? | High 149 (22.1) Moderate 364 (54) Low 161 (23.9) |
No | Statement | Participants’ Response n (%) | ||||
---|---|---|---|---|---|---|
Strongly Agree | Agree | Not Sure | Disagree | Strongly Disagree | ||
1 | Vaccines are necessary to overcome the COVID-19 pandemic and get back to normal life. | 283 (42) | 211 (31.3) | 148 (22) | 17 (2.5) | 15 (2.2) |
2 | I trust COVID-19 vaccines of ONLY certain companies. | 129 (19.2) | 161 (23.9) | 310 (46) | 40 (5.9) | 34 (5) |
3 | I think that vaccines against COVID-19 have been produced in a hurry without following recommended clinical trials and approval guidelines. | 81 (12) | 149 (22.1) | 247 (36.7) | 124 (18.4) | 73 (10.8) |
4 | I think that the companies involved in the development of the COVID-19 vaccines are doing it to make money. | 85 (12.6) | 172 (25.5) | 273 (40.5) | 107 (15.9) | 37 (5.5) |
5 | I think that COVID-19 vaccines may have side effects which may show immediately or later on in life. | 82 (12.1) | 220 (32.6) | 304 (45.1) | 56 (8.3) | 12 (1.8) |
6 | I think companies producing COVID-19 vaccines are open about disclosing information on the side effects of the vaccine. | 62 (9.2) | 212 (31.5) | 325 (48.2) | 61 (9.1) | 14 (2) |
7 | I am happy with the way the health authorities have been managing the COVID-19 pandemic so far. | 409 (60.7) | 211 (31.3) | 35 (5.2) | 14 (2.1) | 5 (0.7) |
8 | I am happy with the health authorities’ efficient organization of the COVID-19 vaccination campaigns through the digital applications and other methods. | 378 (56.1) | 240 (35.6) | 43 (6.4) | 8 (1.2) | 5 (0.7) |
No | Statement | Participants’ Response n (%) | ||||
---|---|---|---|---|---|---|
Strongly Agree | Agree | Not Sure | Disagree | Strongly Disagree | ||
1 | I support a mandatory vaccination program for COVID-19. | 227 (33.6) | 169 (25.1) | 152 (22.6) | 80 (11.9) | 46 (6.8) |
2 | I will get vaccinated with the COVID-19 vaccine. | 273 (40.5) | 159 (23.6) | 180 (26.7) | 40 (5.9) | 22 (3.3) |
3 | I will wait for other people to take the COVID-19 vaccine, as I am afraid to take it myself. | 55 (8.2) | 139 (20.6) | 147 (21.8) | 193 (28.6) | 95 (14.1) |
4 | I will delay taking the COVID-19 vaccine, as I feel there are others who deserve it more than me. | 124 (18.4) | 243 (36.1) | 135 (20) | 82 (12.2) | 45 (6.7) |
5 | Getting myself vaccinated against COVID-19 is important because I can also protect people with a weaker immune system. | 271 (40.2) | 255 (37.8) | 115 (17.1) | 17 (2.5) | 14 (2.1) |
6 | I will take the COVID-19 vaccine only if it is free. | 97 (14.4) | 113 (16.8) | 169 (25.1) | 163 (24.2) | 85 (12.6) |
7 | Compared to the first dose of the COVID-19 vaccine, I fear that the second dose may have more chances to induce adverse side effects. | 54 (8) | 136 (20.2) | 320 (47.5) | 93 (13.8) | 33 (4.9) |
% (n) | p | |
---|---|---|
All Participants | 64.4% (433/672) | |
Age | 0.015 * | |
18–29 years | 61.5% (241/392) | |
30–49 years | 66.7% (166/249) | |
50 years or above | 83.9% (26/31) | |
Sex | 0.034 ** | |
Male | 68.2% (238/349) | |
Female | 60.4% (195/323) | |
Nationality | 0.08 ** | |
Saudi | 67% (274/409) | |
Non-Saudi | 60.5% (159/263) | |
Medical condition | 0.30 ** | |
Healthy | 63.6% (364/572) | |
Has systemic disease/s | 69% (69/100) | |
Previously infected with COVID-19 | 0.08 ** | |
No | 65.8% (375/570) | |
Yes | 56.9% (58/102) | |
Updating self on the development of vaccines against COVID-19 | <0.001 ** | |
No | 49.5% (55/111) | |
Yes | 67.4% (378/561) | |
Opinion about the severity of COVID-19 | 0.001 * | |
Mild | 48% (12/25) | |
Moderate | 59.4% (186/313) | |
Severe | 70.4% (235/334) | |
Compliance with COVID-19 preventive guidelines | 0.018 * | |
Poor | 42.9% (6/14) | |
Moderate | 59.7% (111/186) | |
Good | 66.9% (316/472) | |
Anxiety about contracting COVID-19 | 0.011 * | |
Low | 55.3% (89/161) | |
Moderate | 66.7% (242/363) | |
High | 68.9% (102/148) |
Odds Ratio (95% Confidence Interval) | p | |
---|---|---|
Age | ||
18–29 years | Ref | |
30–49 years | 1.31 (0.87–1.96) | 0.20 |
50 years or above | 2.86 (1.01–8.06) | 0.047 * |
Sex | ||
Male | Ref | |
Female | 0.72 (0.51–1.01) | 0.054 |
Nationality | ||
Saudi | Ref | |
Non-Saudi | 0.58 (0.40–0.85) | 0.005 * |
Medical condition | ||
Healthy | Ref | |
Has systemic disease/s | 1.09 (0.67–1.78) | 0.73 |
Previously infected with COVID-19 | ||
No | Ref | |
Yes | 0.76 (0.48–1.19) | 0.23 |
Updating self on the development of vaccines against COVID-19 | ||
No | Ref | |
Yes | 1.90 (1.23–2.94) | 0.004 * |
Opinion about the severity of COVID-19 | ||
Mild | Ref | |
Moderate | 1.41 (0.59–3.36) | 0.44 |
Severe | 1.86 (0.76–4.55) | 0.17 |
Compliance with COVID-19 preventive guidelines | ||
Poor | Ref | |
Moderate | 2.02 (0.65–6.28) | 0.22 |
Good | 1.74 (0.55–5.48) | 0.35 |
Anxiety about contracting COVID-19 | ||
Low | Ref | |
Moderate | 1.40 (0.84–2.32) | 0.19 |
High | 1.42 (0.94–2.13) | 0.09 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Noushad, M.; Nassani, M.Z.; Alsalhani, A.B.; Koppolu, P.; Niazi, F.H.; Samran, A.; Rastam, S.; Alqerban, A.; Barakat, A.; Almoallim, H.S. COVID-19 Vaccine Intention among Healthcare Workers in Saudi Arabia: A Cross-Sectional Survey. Vaccines 2021, 9, 835. https://doi.org/10.3390/vaccines9080835
Noushad M, Nassani MZ, Alsalhani AB, Koppolu P, Niazi FH, Samran A, Rastam S, Alqerban A, Barakat A, Almoallim HS. COVID-19 Vaccine Intention among Healthcare Workers in Saudi Arabia: A Cross-Sectional Survey. Vaccines. 2021; 9(8):835. https://doi.org/10.3390/vaccines9080835
Chicago/Turabian StyleNoushad, Mohammed, Mohammad Zakaria Nassani, Anas B. Alsalhani, Pradeep Koppolu, Fayez Hussain Niazi, Abdulaziz Samran, Samer Rastam, Ali Alqerban, Ali Barakat, and Hesham S. Almoallim. 2021. "COVID-19 Vaccine Intention among Healthcare Workers in Saudi Arabia: A Cross-Sectional Survey" Vaccines 9, no. 8: 835. https://doi.org/10.3390/vaccines9080835
APA StyleNoushad, M., Nassani, M. Z., Alsalhani, A. B., Koppolu, P., Niazi, F. H., Samran, A., Rastam, S., Alqerban, A., Barakat, A., & Almoallim, H. S. (2021). COVID-19 Vaccine Intention among Healthcare Workers in Saudi Arabia: A Cross-Sectional Survey. Vaccines, 9(8), 835. https://doi.org/10.3390/vaccines9080835